ArticleOphthalmology and therapy2026
Faricimab Improves Choriocapillaris Perfusion in Diabetic Macular Edema.
Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionThis study is a retrospective observational study to evaluate the effects of intravitreal faricimab on choriocapillaris perfusion in diabetic macular edema (DME) using optical coherence tomography angiography (OCTA) and to investigate the relationship between changes in choriocapillaris flow void (CCFV) and visual outcomes.
methodsEyes with center-involved DME that received four consecutive monthly intravitreal faricimab injections were included. OCTA (Solix FullRange®) was obtained within 1 month before the first injection and 1 month after the fourth injection. The choriocapillaris (CC) slab was segmented per device default, and CCFV was quantified after Phansalkar local thresholding. Additional metrics included central retinal thickness (CRT), subfoveal choroidal thickness (sfChT), and choroidal vascularity index in Sattler's (CVI_S) and Haller's layers (CVI_H). Pre/post differences were tested with paired t-tests, and Pearson correlation analyses were performed to assess the associations of changes in CCFV with changes in structural optical coherence tomography (OCT) parameters and best-corrected visual acuity (BCVA).
resultsThirty eyes were analyzed. Mean CCFV decreased from 53.35 to 48.89%, yielding a mean reduction of 4.46% (95% confidence interval [CI], -6.37 to -2.56; P < 0.001). BCVA improved significantly (mean difference, -0.20 logMAR; 95% CI -0.27 to -0.12; P < 0.001). CRT decreased from 483.43 ± 72.26 to 313.93 ± 58.41 µm (mean difference, -169.50 µm; P < 0.001). sfChT also decreased significantly (mean difference, -35.56 µm; P < 0.001). CVI_H increased significantly (mean difference, 2.71 percentage points; P < 0.001), whereas CVI_S showed a slight but non-significant increase (mean difference, 0.62 percentage points; P = 0.483). No significant correlations were observed between changes in CCFV and those in CRT, sfChT, CVI_S, or CVI_H (all P > 0.05). However, changes in CCFV were positively correlated with changes in BCVA (r = 0.437, 95% CI 0.091-0.689; P = 0.016), with greater reductions in CCFV associated with greater visual acuity improvement.
conclusionsFaricimab was associated with a significant reduction in CCFV, suggesting improved choriocapillaris perfusion accompanied by significant anatomical and functional improvements in DME. The significant association between changes in CCFV and visual acuity improvement suggests that OCTA-derived CCFV may serve as a functional biomarker of treatment response. These findings support the concept that restoration of choriocapillaris perfusion may contribute to visual recovery and highlight the role of the choroid in DME beyond retinal edema resolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.